About the Fund

Investment Criteria

$100k to $500k initial investment
Convertible debt or equity
Phase I: Health Innovation (Current)

Health Equity, Physician Referral, Physician/Clinical Experience, Patient Experience

Phase 2: Multi-Market Tech (2022)

Education, Finance & Insurance, Supply Chain, Transportation & Mobility, Other

Graduate of a recognized accelerator, and/or previously funded
Humbly confident and experienced management team
Large and growing addressable market
Demonstrated product-market fit
Innovative and defensible tech/IP
Profitable unit economics at scale
Likely exit pathways


Operations in the broader Mid-Atlantic region

Contact Our Team

Paul Nolde

Fund Manager/Managing Director
Investment Committee Chair


Board Members

Monique Adams*

Executive Director, 757 Angels
Chandra Briggman

Chandra Briggman

CEO, Activation Capital
RGF Board Chair

Jim Cheng*

Investor and Exited Entrepreneur

Dave Levin, M.D.*

Chief Medical and Information Officer, Phlow Corp.

Bob Mooney*

Co-Founder / Managing Director, NRV

*Investment Committee

Portfolio Companies

DrugViu is generating the most comprehensive data for autoimmune research by combining medical records with validated patient-reported outcomes, a proprietary autoimmune biorepository and access to patients for clinical research.

Floreo is leveraging the power of Virtual Reality to provide a method of teaching social, behavioral, communication and life skills for individuals with Autism Spectrum Disorder (ASD) and related diagnoses.